Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Chlebowski

Showing results (71-80 of 379) with videos related to

Pageof 38
Sort By:
Cancer|March 27, 2020
Forty-year trends in menopausal hormone therapy use and breast cancer incidence among postmenopausal black and white womenRowan T Chlebowski, Aaron K Aragaki, Garnet L Anderson, et al.
Cancer|October 15, 1981
Treatment of advanced breast carcinoma with 5-fluorouracil: a randomized comparison of two routes of deliveryR T Chlebowski, R P Pugh, J M Weiner, et al.
Ethnicity & Disease|November 9, 2018
Breast Cancer Outcomes in a Racially and Ethnically Diverse Cohort of Insured WomenReina Haque, Xiaoqing Xu, Jiaxiao Shi, et al.
Cancer Practice|November 1, 1993
Factors influencing nurses' breast cancer control activityL B Lillington, G V Padilla, J W Sayre, et al.
Cancer|March 12, 2015
Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivorsRowan T Chlebowski, Joanne E Schottinger, Jiaxiao Shi, et al.
Breast Cancer (Dove Medical Press)|August 22, 2023
Risk of Subsequent Breast Cancer in Women with Early Stage HER2-Positive Breast Cancer in a Large Community Health PlanReina Haque, Lie Hong Chen, Nina Oestreicher, et al.
Cancer|December 1, 1978
Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer: a randomized trialR T Chlebowski, R Hestorff, L Sardoff, et al.
Cancer|January 20, 2011
Comorbidities and mammography use interact to explain racial/ethnic disparities in breast cancer stage at diagnosisShagufta Yasmeen, Guibo Xing, Cyllene Morris, et al.
Cancer Treatment Reports|April 1, 1984
Abnormal deoxyuridine suppression as a rapid predictor for antimetabolite chemosensitivity: correlation with in vitro tests of growth inhibitionJ B Block, R T Chlebowski, M F Dietrich, et al.
Controlled Clinical Trials|June 1, 1981
Factors influencing the interim interpretation of a breast cancer trial: danger of achieving the "expected" resultR T Chlebowski, J M Weiner, V M Ryden, et al.
Pageof 38

Showing results (71-80 of 379) with videos related to

Sort By:
Pageof 38
Cancer|March 27, 2020
Forty-year trends in menopausal hormone therapy use and breast cancer incidence among postmenopausal black and white womenRowan T Chlebowski, Aaron K Aragaki, Garnet L Anderson, et al.
Cancer|October 15, 1981
Treatment of advanced breast carcinoma with 5-fluorouracil: a randomized comparison of two routes of deliveryR T Chlebowski, R P Pugh, J M Weiner, et al.
Ethnicity & Disease|November 9, 2018
Breast Cancer Outcomes in a Racially and Ethnically Diverse Cohort of Insured WomenReina Haque, Xiaoqing Xu, Jiaxiao Shi, et al.
Cancer Practice|November 1, 1993
Factors influencing nurses' breast cancer control activityL B Lillington, G V Padilla, J W Sayre, et al.
Cancer|March 12, 2015
Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivorsRowan T Chlebowski, Joanne E Schottinger, Jiaxiao Shi, et al.
Breast Cancer (Dove Medical Press)|August 22, 2023
Risk of Subsequent Breast Cancer in Women with Early Stage HER2-Positive Breast Cancer in a Large Community Health PlanReina Haque, Lie Hong Chen, Nina Oestreicher, et al.
Cancer|December 1, 1978
Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer: a randomized trialR T Chlebowski, R Hestorff, L Sardoff, et al.
Cancer|January 20, 2011
Comorbidities and mammography use interact to explain racial/ethnic disparities in breast cancer stage at diagnosisShagufta Yasmeen, Guibo Xing, Cyllene Morris, et al.
Cancer Treatment Reports|April 1, 1984
Abnormal deoxyuridine suppression as a rapid predictor for antimetabolite chemosensitivity: correlation with in vitro tests of growth inhibitionJ B Block, R T Chlebowski, M F Dietrich, et al.
Controlled Clinical Trials|June 1, 1981
Factors influencing the interim interpretation of a breast cancer trial: danger of achieving the "expected" resultR T Chlebowski, J M Weiner, V M Ryden, et al.
Pageof 38